Ocean Biomedical Announces Grant on Patent Right for Bispecific Antibodies Targeting CHI3L1 and PD1 for Enhanced Tumor Cell Cytotoxicity in China

Core Viewpoint - Ocean Biomedical, Inc. has received a patent grant from the China National Intellectual Property Administration for its bispecific antibodies targeting CHI3L1 and PD1, which are designed to enhance T cell-mediated cytotoxic effects on tumor cells [1][2]. Group 1: Patent and Intellectual Property - The newly issued patent strengthens Ocean Biomedical's intellectual property portfolio and provides protection in one of the largest pharmaceutical markets globally [2]. - The granted claims cover the novel design and therapeutic applications of bispecific antibodies that inhibit CHI3L1 and PD1, which are key targets in immune evasion by tumor cells [2][3]. - This patent follows the company's success in securing intellectual property protection in key markets, including the United States and Europe [5]. Group 2: Technology and Innovation - Ocean Biomedical's bispecific antibody technology represents a potential paradigm shift in cancer immunotherapy by targeting both CHI3L1 and PD1, which could enhance the immune system's ability to combat tumors more effectively [3]. - By blocking both pathways, these antibodies may lead to more durable responses and better patient outcomes compared to existing treatments [3][4]. - The technology aims to address limitations of current immunotherapies, which are often hindered by tumor resistance and immune evasion mechanisms [4]. Group 3: Strategic Goals and Collaborations - The patent grant is viewed as a significant milestone in the company's global expansion strategy, highlighting the novelty and therapeutic potential of its bispecific antibody platform [4]. - The company plans to continue collaborating with leading researchers, biopharma partners, and regulatory agencies to accelerate the translation of its discoveries into transformative therapies [6].